Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 18395047.
- Also identified by DOI 10.1016/j.ajog.2007.12.028 and PMC identifier 2346589.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to examine the functional and therapeutic significance of pericytes in ovarian cancer vasculature. Tumor vessel morphologic condition and efficacy of endothelial and pericyte targeting were examined with the use of in vivo ovarian cancer models. The expression of platelet-derived growth factor (PDGF) ligands and receptors was examined in endothelial, pericyte-like, and ovarian cancer cells. Relative to normal vessels, tumor vasculature was characterized by loosely attached pericytes in reduced density. PDGF-BB was expressed predominantly by the endothelial and cancer cells, whereas PDGFRbeta was present in pericyte-like cells. PDGF-BB significantly increased the migration of and VEGF production by pericyte-like cells; PDGFRbeta blockade abrogated these effects. Dual VEGF (VEGF-Trap) and PDGF-B (PDGF-Trap) targeted therapy was more effective in inhibiting in vivo tumor growth than either agent alone. Aberrations in the tumor microenvironment contribute to endothelial cell survival. Strategies that target both endothelial cells and pericytes should be considered for clinical trials.
Medical subject headings
- Angiogenesis Inhibitors
- Endothelial Cells
- Neovascularization, Pathologic
- Ovarian Neoplasms
- Pericytes